Rubicon Research has secured Rs 619 crore from anchor investors, including global giants like Goldman Sachs, ahead of its Rs 1,377.5 crore IPO. The pharmaceutical firm’s public offering opens October 9, aiming to raise funds for debt repayment and strategic growth. The company, focused on R&D and specialty products for regulated markets, expects its stock market debut on October 16.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets